RT Journal Article
SR Electronic
T1 Intravenous immunoglobulin therapy for Miller Fisher syndrome
JF Neurology
JO Neurology
FD Lippincott Williams & Wilkins
SP 1144
OP 1146
DO 10.1212/01.wnl.0000258673.31824.61
VO 68
IS 14
A1 Mori, Masahiro
A1 Kuwabara, Satoshi
A1 Fukutake, Toshio
A1 Hattori, Takamichi
YR 2007
UL http://n.neurology.org/content/68/14/1144.abstract
AB We analyzed clinical recovery of 92 patients with Miller Fisher syndrome who had been treated with IV immunoglobulin (IVIg; n = 28), plasmapheresis (n = 23), and no immune treatment (n = 41). IVIg slightly hastened the amelioration of ophthalmoplegia and ataxia, but the times of the disappearances of those symptoms were similar among three groups. In Miller Fisher syndrome, IVIg and plasmapheresis seem not to have influenced patients' outcomes, presumably because of good natural recovery.